

# History of MHC – 1971 – 2011

1971

1971

[HL-D](#)


TABLE 3. *One-way MLR of HL-A identical mother and son (a = Minnesota family H), two-way MLR of HL-A-identical father and son (b = Duke family Q-H), and grandfather and grandson (c = Duke family 0035)*

Responding cells	Am	Bm	Xm
(a) A (2-12/3-7) mother	205	3,421	4,321
B (2-12/3-7) son	3,124	328	4,858
X (1,8,2,12) unrelated	17,428	20,342	784
	<i>Father</i>	<i>Son</i>	<i>Unrelated</i>
(b) Father (1-7/2-5)	1,205	20,809	54,545
Son (1-7/2-5)	—	2,337	100,061
Unrelated (11-W18/Ao54- )	—	—	4,569
	<i>Grand- father</i>	<i>Grandson</i>	<i>Unrelated</i>
(c) Grandfather (Ao77-12/1-8)	420	7,438	34,825
Grandson (Ao77-12/1-8)	—	264	14,501
Unrelated (9-5/10- )	—	—	433

In 1971, Yunis and Amos ([Proc Nat Acad Sci USA 68:3031, 1971](#)) showed that the mixed leukocyte reaction (MLR) was controlled by an independent locus (HL-D), centromeric to the serologically detected HL-B.

1971

[Chromosome 17](#)



The H-2 complex was assigned to mouse chromosome 17 by Miller et al. ([Proc Natl Acad Sci USA 68:1530, 1971](#))

1972

1972

### HLA and Human Diseases

**Table 1. HL-A Antigen Frequency in Unrelated 44 Caucasian Psoriatic Patients and 89 Controls.**

ANTIGEN	PERCENTAGE POSITIVE	
	CONTROLS	PATIENTS
HL-A1	28.1	29.5
HL-A2	48.3	56.8
HL-A3	25.8	31.8
HL-A9	19.1	15.9
HL-A10	13.5	13.6
HL-A11	15.7	9.1
W28 (Te40)*	7.9	6.8
W29 (Te63)	5.6	4.5
W30 (Te66)	6.7	9.1
W32 (Te59)	6.7	2.3
HL-A5	15.7	9.1
HL-A7	20.2	18.2
HL-A8	20.2	13.6
HL-A12	24.7	22.7
HL-A13	3.4	27.3*
W5 (Te50)	16.9	18.2
W10 (Te60)	13.5	18.2
W14 (Te54)	6.7	4.5
W15 (Te55)	13.5	11.4
W17 (Te57)	9.0	22.7*
W18 (Te58)	10.1	4.5
W22 (Te51)	4.5	0.0
W27 (Te52)	10.1	13.6

\*Nomenclature before 5th International Conference on Histocompatibility. Evian, France, May 23-27, 1972.

\*Significantly different from controls ( $p < 0.0001$ ).

\*Significantly different from controls ( $p = 0.056$ ).


Three groups published their data on the possible association of HLA with human diseases: Falchuck et al (J Clin Invest 51:1602, 1972) reported that the frequency HLA-B8 was

increased in patients with celiac disease while Russell et al. ([N Engl J Med 287:738, 1972](#)) and White et al ([N Engl J Med 287:740. 1972](#)) showed an association of HLA-B13 and B17 with psoriasis.

1973

1973

### [Linked Ir Genes](#)



Allan Rosenthal and Ethan Shevach ([J Exp Med 136: 1207, 1972](#); [J Exp Med 138: 1194](#) and [1213, 1973](#)) demonstrated that antigen recognition by guinea pig T cells was regulated by macrophages and restricted by the MHC class II linked Ir genes.

1973

### [Ankylosing Spondylitis](#)

**Table 1. Phenotype Frequencies of HL-A Specificities in Ankylosing Spondylitis (AS), Rheumatoid Arthritis (RA) and Gout (All Caucasian).**

ANTIGEN	% IN 906 CONTROLS	% IN 40 PATIENTS WITH AS	% IN 119 PATIENTS WITH RA	% IN 66 PATIENTS WITH GOUT
HL-A1	27	10	28	36
HL-A2	48	60	49	44
HL-A3	24	18	26	30
HL-A9	22	30	20	18
HL-A10	11	8	17	12
HL-A11	12	10	10	6
W28	12	18	8	12
W29	7	10	8	8
W30	10	15	10	6
W32	8	13	5	6
HL-A5	11	5	3	14
HL-A7	25	3*	13	27
HL-A8	21	15	14	21
HL-A12	24	18	22	24
HL-A13	4	3	8	6
W5	22	18	25	17
W10	14	18	10	8
W14	7	5	8	8
W15	8	8	11	8
W17	8	5	13	17
W18	9	5	6	9
W21	5	3	0	2
W22	5	3	3	5
W27	8	88†	8	9


\*Chi square = 9.32 (p<0.05 when multiplied by 24).

†Chi square = 236.41 (p<0.0001 when multiplied by 24, no. of specificities tested).

A strong association of HLA-B27 and Ankylosing Spondylitis was reported by Caffrey and James ([Nature 242:121, 1973](#)), Brewerton et al. ([Lancet 1\(7809\):904, 1973](#)) and Schlosstein et al ([N Engl J Med 288:704, 1973](#))

1973

HLA-DR




The HLA-DR (HLA-D Related) antigens were serologically detected on B lymphocytes using immunofluorescence ([van Leeuwen et al., Transplant Proc 5:1539: 1973](#))

1974

1974

MHC Restriction




In 1974, Peter Doherty and Rolf Zinkernagel published a series of papers ([Nature 248:701, 1974](#); [Nature 251: 547, 1974](#)) demonstrating that recognition of viral infected target cells by CD8+ T cells is restricted by MHC class I genes. They put forward the concept of 'MHC restriction'.

1974



## HLA Complex



In 1974, van Someren et al. ([Proc Natl Acad Sci USA 71:962, 1974](#)) and Lamm et al. ([Hum Hered 24:273, 1974](#)) assigned the HLA complex to human chromosome 6.

1974

## Gene Linkage




FIG. 1. Pedigree of the S family. The heterozygous and homozygous C2-deficient cases are indicated by the solid black symbols and the HLA-A type is given in adjoining space.


Fu et al. ([J Exp Med 140:1108, 1974](#)) demonstrated a linkage between HLA and the gene responsible for complement component C2. Allen ([Vox Sang 27:382, 1974](#)) reported that the complement

Factor B (Bf) gene is in linkage with HLA genes.

1975

1975


B2-microglobulin



Goodfellow et al. ([Nature 254:267, 1975](#)) and Smith et al. ([Am J Hum Genet 39:21, 1975](#)) assigned the human b2-microglobulin locus to chromosome 15.

1975

Diabetes




Family with two diabetic siblings showing cross-over between first and second HL-A loci.

The association of Type I diabetes (IDDM) and HLA was first

reported by Singal et al. ([Diabetes 22:429, 1973](#)) and confirmed by the classical studies of Nerup and colleagues ([Lancet 2\(7885\): 864, 1974](#)) and Cudworth and Woodrow ([Br Med J 3:133, 1975](#)).

1975

[Linkage](#)



Rittner and colleagues (Histocompatibility Testing, p945, 1975) demonstrated a linkage between HLA genes and the complement component C4.

1977

1977

[Antigen Recognition](#)



In 1977, Els Goulmy et al. ([Nature 266:544, 1977](#)) demonstrated




that antigen recognition by CD8 T cells was restricted by class I molecules, while Bergholtz and Thorsby ([Scand J Immunol 6:779, 1977](#)) showed that class II molecules restrict antigen recognition by CD4 T cells.

1978

1978

[alpha and beta chains](#)



The class II  $\alpha$  and  $\beta$  chains were identified during the late 1970s by many groups, for both H-2 ([Cullen et al. Transplantation 30:236, 1976](#); [Freed et al. J Immunol 121:91, 1978](#); [Cook et al. J Immunol 123:2799, 1979](#)) and HLA-DR systems ([Humpreys et al. J Exp Med 144:98, 1976](#); [Kaufman and Strominger, Proc Natl Acad Sci USA 576:6304, 1979](#)).

1978

[HLA-DR matching](#)

---

**Table 3. Predictors of Graft Failure**

<b>Predictor</b>	<b>Hazard Ratio (95% CI)</b>	<b>P Value</b>
0-HLA-DR mismatch	1 [Reference]	
1- or 2-HLA-DR mismatches	0.5 (0.1-2.2)	.40
Recipient race		>.05
Age at transplantation, y		
<13	1 [Reference]	
13-16	8.9 (2.4-32.5)	.001
>16	8.4 (1.9-37.1)	.005
History of rejection	7.7 (1.6-37.7)	.01
Posttransplantation lymphoproliferative disorder	46.6 (6.9-312.0)	<.001

---

Abbreviation: CI, confidence interval.

---

Ting and Morris ([Lancet 1\(8064\):575, 1978](#)) and Albrechtsen et al. ([Lancet 2\(8100\):1226, 1978](#)) reported a strong effect of HLA-DR matching on kidney graft survival.

1979

1979

[Invariant Chain](#)




Jones et al., ([Mol Immunol 16:51, 1979](#)) reported the existence of an invariant chain (Ii) that binds the  $\alpha$  and  $\beta$  class II

chains in the endoplasmic reticulum (ER), before the trimer moves to the Golgi apparatus.

1980

1980

[1980 Nobel Prize](#)



In 1980, Jean Dausset, George Snell and Baruj Benacerraf were awarded the Nobel Prize in Medicine and Biology for their discoveries on the MHC. Peter Gorer could not make the list because he had passed away in 1961.

[Nobel Prize 1980](#) – Discoveries concerning genetically determined structures on the cell surface that regulate immunological reactions.

1982

1982

[Collaborative Transplant Study](#)



In 1982, Gerhard Opelz, at the University of Heidelberg (Germany), launched the Collaborative Transplant Study (CTS), an international collaborative program involving a large number of transplant groups and tissue typing laboratories. The data collected through CTS clearly demonstrated an important effect of HLA matching on kidney graft survival. The CTS has been a great source of very important information on factors influencing long-term graft survival following organ transplantation.

1983

1983

[Flow Cytometry](#)

## **TRANSPLANTATION PROCEEDINGS**

Garovoy et al. (Transplant Proc: 15:1939, 1983) introduced flow cytometry as the more sensitive technique for the pre-transplant crossmatch analysis.

1983

[Single Recombinant HLA](#)




Bernabeu et al. ([J Immunol 131:2032, 1983](#)) reported the production of single recombinant HLA molecules, opening the possibility to use these molecules for the detection of antigen-specific responses.

1985

1985

[H-2k and I-Ak molecules](#)




In 1985, Emil Unanue and his colleagues described the characteristics of the peptides binding H-2<sup>k</sup> (Class I) ([J Immunol 135:368, 1985](#)) and I-A<sup>k</sup> (Class II) ([Nature 317:359, 1985](#)) molecules.

1987

1987

[HLA bind antigenic peptides](#)




In 1987, Pamela Bjorkman, Jack Strominger and colleagues reported the three-dimensional structure of HLA-A2 by X-ray crystallography ([Nature 329: 506, 1987](#); and [329:512, 1987](#)). They demonstrated that polymorphic amino acid residues located in the floor or side chains of the peptide binding groove of HLA class I molecules bind antigenic peptides in specific residues, while other residues bind the T-cell receptor (TCR).

1988

1988

### [3D HLA Class II Molecules](#)






The three-dimensional structure of the HLA Class II molecules was proposed by Brown et al. in 1988 ([Nature 332:845, 1988](#)) and confirmed by the same group for HLA-DR1 ([Nature 364:33, 1993](#)).

1990

1990


[CLIP](#)



Roche and Creswell ([Nature 345:615, 1990](#)) demonstrated that a part of the invariant chain Ii, the class II-associated Ii peptide (CLIP), temporarily blocks the peptide-binding groove of nascent class II molecules.

1990

[TAP](#)




In 1990, three groups simultaneously demonstrated that a gene located on the class II region regulates the class I antigen presentation ([Deverson et al., Nature 348:738, 1990](#); [Trowsdale et al., Nature 348:741, 1990](#); [Spies et al., Nature 348:744, 1990](#)). The gene codes for an ATP-binding cassette (ABC) superfamily of transporter proteins that transport peptides from the cytoplasm into the ER, where peptides are loaded into

nascent class I molecules. The protein was named TAP.

1990

### Acute Rejection




## **Kidney Transplant**

In 1990, Halloran and colleagues ([Transplantation 49:85:1990](#)) demonstrated that *de novo* produced, donor-specific HLA class I antibodies can induce acute rejection of kidney grafts.

1991

1991



LMP



In 1991, a proteasome gene was found in the HLA class II region ([Glynne et al, Nature 353:357, 1991](#)). Soon after, Rock et al ([Cell 78:761, 1994](#)) demonstrated that the low molecular weight proteasome (LMP) was involved in the generation of peptides that are then transported into the ER by TAP.

1991

[Direct Allorecognition](#)



In 1991 Rotzschke et al ([J Exp Med 174:1059, 1991](#)) demonstrated that cytotoxic T lymphocytes could directly recognize allogeneic MHC-peptide complexes, without presentation by autologous antigen presenting cells. This phenomenon is known as direct allorecognition.

1992

1992

[Polymerase Chain Reaction](#)





Figure 1. PCR-SSCP analysis of HLA-DQA1 group alleles. Lane 1: Molecular weight  
 Following the development of the Polymerase Chain Reaction (PCR) by Saiki ([Science 230:1350, 1985](#)), several DNA based procedures were developed for molecular HLA typing. This includes: Sequence Specific Oligo hybridization (SSOP) ([Wordsworth, Immunol Lett 29:37, 1991](#)), PCR based Sequence Specific Primer technology or PCR-SSP ([Olerup and Zetterquist, Tissue Antigens 39:225, 1992](#)), PCR-Single Strand Conformation Polymorphisms or SSCP ([Carrington et al., Hum Immunol 33:208, 1992](#)), and Sequence Based Typing or SBT ([Cereb et al., Tissue Antigens 45:1, 1995](#)). These molecular methods have since replaced the serological methods for HLA typing in most clinical laboratories.

1993  
 1993  
[ELISA](#)





In 1993, Kao et al ([Transplantation 55:192, 1993](#)) introduced ELISA as an immunoassay for the detection of anti-HLA antibodies.

1993

[Bare Lymphocyte Syndrome](#)



In 1993, Steimie et al ([Cell 75:135, 1993](#)) demonstrated that




the 'Bare Lymphocyte Syndrome', characterized by the complete lack of HLA class II expression leading to severe combined immunodeficiency, is caused by deletion in a gene that regulates the expression of class II molecules, the Class II Transactivator (CIITA).

1995

1995

### [Chronic Rejection](#)



In 1995 Buchler et al ([Transplant Proc 27:2478, 1995](#)) reported that the development of post-transplant anti-HLA antibodies is associated with chronic rejection.

1996

1996

### [1996 Nobel Prize](#)




In 1996, Peter Doherty and Rolf Zinkernagel shared the Nobel Prize for Medicine and Biology for their discovery on the role of MHC class I antigens in the recognition of viral-infected target cells by CD8+ T cells and “MHC restriction”.

[Nobel Prize 1996](#) – discoveries concerning the specificity of the cell mediated immune defence

1997

1997

[Multiplex Analysis](#)




In 1997, Fulton et al ([Clin Chem 43:1749, 1997](#)) introduced the multiplex analysis technique for detection of HLA antibodies.



2002

2002

[HLA Matchmaker algorithm](#)



In 2002, Rene Duquesnoy ([Human Immunol 63:339, 2002](#)) introduced the HLA Matchmaker algorithm that allows to calculate the level of HLA sensitization.

2002

[HLA Antibodies](#)



**Table 2** Donor-Specific Antibody in Study Cohort

Pt	Sensitized CPRA >20%	VXM By IgG-SAB	By C1q-SAB	DSA		By C1q-SAB at Tx	By C1q-SAB
				By IgG-SAB at Tx	By IgG-SAB		
2	Yes	Pos	NT	1	B51	NT	...
6	Yes	Pos	Pos	2	A2, DR51	1	A2
7	No	Neg	NT	0	...	NT	...
10	Yes	Pos	Neg	1	DR4	0	...
11	No	Neg	NT	0	...	NT	...
12	Yes	Pos	Pos	8	A23, A32, B35, B45, DR1, DR11, DQ5, DQ6	3	A23, A32, B45
13	Yes	Pos	Neg	2	DR13, DR14	0 (1) <sup>a</sup>	(DR13) <sup>a</sup>
14	No	Neg	NT	0		NT	
15	Yes	Pos	Neg	6	A29, A32, B44, B51, Cw15, DP2	0 (2) <sup>a</sup>	(B44, B51) <sup>a</sup>
16	Yes	Pos	Neg	3	A24, B61, DR12	0	...
17	No	Neg	Neg	0		NT	...
18	No	Neg	Neg	0		NT	...
19	Yes	Pos	Neg	1	B7	0	...
20	Yes	Neg	Neg	0		NT	...
22	Yes	Pos	Pos	7	A25, A68, B44, B52, DR13, DR14, DQ6	1	A68
23	Yes	Pos	Neg	2	DR4, DQ6	0	...
24	Yes	Neg	Neg	0	...	NT	...
25	Yes	Pos	Neg	6	Cw16, DR7, DR52, DR53, DP13, DP14	0	...


CPRA, calculated percent panel reactive antibody; DSA, donor-specific antibody; NT, not tested; SAB, single-antigen bead assay; Tx, transplant; VXM, virtual crossmatch.

<sup>a</sup>Historically present, desensitized, absent at transplant, rebound after transplant.

In 2011, Chin et al ([J Heart Lung Transplant 30:158, 2011](#)) introduced the C1q binding assay for detection of Complement-activating HLA antibodies.

2011

### [Nomenclature](#)



In 2011 the WHO Nomenclature Committee for Factors of the HLA System updated the rules for the nomenclature of HLA loci and alleles ([Marsh, Tissue Antigens 78:482, 2011](#); <http://hla.alleles.org/nomenclature/naming>). Presently, >18000 HLA alleles (HLA class I 13,324 and HLA class II 4857 have



become known primarily due to extensive improvements in molecular based technologies.

The next two decades will see developments in regenerative medicine/biology to re-create and/or repair damaged organs and a switch from standard to patient specific treatment.

Immunogenetics of the host, beyond MHC will make us understand why some organs survive despite having so many so many incompatibilities, while others are lost even though they are optimally matched. Prediction will become the key word for transplantation.

### ***Acknowledgement***

*History kindly supplied by Dr Luis Garcia – Immunopaedia Steering Committee and Narinder K Mehra – All India Institute of Medical Sciences*

*Luis F García*

*Emeritus Professor*

*Grupo de Inmunología Celular e Inmunogenética*

*Universidad de Antioquia*

*Medellín, Colombia*

*IUIS Education Committee*

*Immunopaedia Steering Committee*

*Narinder K Mehra*

*Ex-head, Department of Transplant Immunology and Immunogenetics*

*All India Institute of Medical Sciences*

*New Delhi, India*